Ullem Scott B. 4
4 · Edwards Lifesciences Corp · Filed Nov 10, 2025
Insider Transaction Report
Form 4
Ullem Scott B.
CVP, Chief Financial Officer
Transactions
- Sale
Common Stock
2025-11-10$83.30/sh−2,974$247,734→ 49,924 total - Exercise/Conversion
Common Stock
2025-11-10$59.26/sh+13,000$770,337→ 52,898 total - Sale
Common Stock
2025-11-10$83.02/sh−10,026$832,360→ 39,898 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2025-11-10−13,000→ 46,700 totalExercise: $59.26From: 2020-05-08Exp: 2026-05-07→ Common Stock (13,000 underlying)
Holdings
- 266,318(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $83.270 to $83.415. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $82.270 to $83.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.